About Novartis AG
https://www.novartis.comNovartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.
CEO
Vasant Narasimhan
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-04-09 | Forward | 279:250 |
| 2000-05-11 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
DODGE & COX
Shares:10.59M
Value:$1.55B
PRIMECAP MANAGEMENT CO/CA/
Shares:9.34M
Value:$1.37B
DIMENSIONAL FUND ADVISORS LP
Shares:8.84M
Value:$1.29B
Summary
Showing Top 3 of 1,905
About Novartis AG
https://www.novartis.comNovartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.36B ▼ | $6.32B ▼ | $3.93B ▼ | 27.36% ▲ | $0.62 ▼ | $5.84B ▼ |
| Q2-2025 | $14.84B ▲ | $6.65B ▲ | $4.04B ▲ | 27.24% ▲ | $2.07 ▲ | $6.08B ▲ |
| Q1-2025 | $13.62B ▲ | $5.73B ▼ | $3.61B ▲ | 26.48% ▲ | $1.83 ▲ | $5.83B ▲ |
| Q4-2024 | $13.56B ▲ | $6.7B ▲ | $2.82B ▼ | 20.78% ▼ | $1.42 ▼ | $5.19B ▼ |
| Q3-2024 | $13.17B | $6.31B | $3.19B | 24.21% | $1.58 | $5.61B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $9.75B ▲ | $107.29B ▲ | $62.54B ▲ | $44.33B ▲ |
| Q2-2025 | $7B ▼ | $104.39B ▲ | $62.34B ▲ | $41.98B ▲ |
| Q1-2025 | $7.2B ▼ | $99.94B ▼ | $61.49B ▲ | $38.37B ▼ |
| Q4-2024 | $13.35B ▼ | $102.25B ▼ | $58.12B ▼ | $44.05B ▲ |
| Q3-2024 | $14.02B | $103.52B | $60.08B | $43.32B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.93B ▼ | $6.57B ▼ | $-860M ▲ | $-2.79B ▲ | $2.9B ▲ | $5.74B ▼ |
| Q2-2025 | $4.02B ▲ | $6.66B ▲ | $-2.24B ▼ | $-5.21B ▲ | $-410M ▲ | $6.11B ▲ |
| Q1-2025 | $3.61B ▲ | $3.65B ▼ | $330M ▲ | $-8.55B ▼ | $-4.39B ▼ | $2.15B ▼ |
| Q4-2024 | $2.82B ▼ | $4.19B ▼ | $-3.03B ▼ | $-3B ▼ | $-2.15B ▼ | $3.06B ▼ |
| Q3-2024 | $3.19B | $6.29B | $-374M | $-382M | $5.71B | $5.49B |
Revenue by Products
| Product | Q2-2020 | Q2-2021 | Q2-2022 | Q2-2023 |
|---|---|---|---|---|
 Rest of portfolio | $2.08Bn ▲ | $2.33Bn ▲ | $2.20Bn ▼ | $2.45Bn ▲ |
 Top 20 products | $7.10Bn ▲ | $8.23Bn ▲ | $8.26Bn ▲ | $8.79Bn ▲ |
 Anti Infectives sold under Sandoz name | $130.00M ▲ | $160.00M ▲ | $180.00M ▲ | $0 ▼ |
 Total antiinfectives net sales | $0 ▲ | $260.00M ▲ | $280.00M ▲ | $0 ▼ |
CEO
Vasant Narasimhan
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-04-09 | Forward | 279:250 |
| 2000-05-11 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
DODGE & COX
Shares:10.59M
Value:$1.55B
PRIMECAP MANAGEMENT CO/CA/
Shares:9.34M
Value:$1.37B
DIMENSIONAL FUND ADVISORS LP
Shares:8.84M
Value:$1.29B
Summary
Showing Top 3 of 1,905